Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Change in Cash (2018 - 2025)

Historic Change in Cash for Whitehawk Therapeutics (WHWK) over the last 8 years, with Q3 2025 value amounting to -$107.0 million.

  • Whitehawk Therapeutics' Change in Cash fell 90929.07% to -$107.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 million, marking a year-over-year increase of 11915.54%. This contributed to the annual value of -$34.2 million for FY2024, which is 24335.75% down from last year.
  • As of Q3 2025, Whitehawk Therapeutics' Change in Cash stood at -$107.0 million, which was down 90929.07% from -$82.6 million recorded in Q2 2025.
  • Whitehawk Therapeutics' Change in Cash's 5-year high stood at $198.8 million during Q1 2025, with a 5-year trough of -$107.0 million in Q3 2025.
  • In the last 5 years, Whitehawk Therapeutics' Change in Cash had a median value of -$5.9 million in 2023 and averaged $1.8 million.
  • Per our database at Business Quant, Whitehawk Therapeutics' Change in Cash tumbled by 175397.82% in 2024 and then skyrocketed by 228308.08% in 2025.
  • Over the past 5 years, Whitehawk Therapeutics' Change in Cash (Quarter) stood at -$12.4 million in 2021, then plummeted by 673.42% to -$95.8 million in 2022, then soared by 93.83% to -$5.9 million in 2023, then skyrocketed by 68.44% to -$1.9 million in 2024, then plummeted by 5631.39% to -$107.0 million in 2025.
  • Its Change in Cash stands at -$107.0 million for Q3 2025, versus -$82.6 million for Q2 2025 and $198.8 million for Q1 2025.